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Purpose/Objective: To determine whether individualization of dose 
prescriptions based on tumor size and location is a feasible approach 
for SBRT-based treatment of non-small cell lung cancer. 
Materials and Methods: Treatment plans for 133 NSCLC patients 
treated using 12 Gy/Fxn x 4, and planned using a pencil-beam (1D-
equivalent-path-length, EPL-1D) algorithm were retrospectively 
calculated with a Monte Carlo (MC)-based algorithm using EPL-1D plan 
parameters. 4D imaging was performed to generate an ITV. PTV 
margin was 5 mm. For each plan, generalized equivalent dose (gEUD) 
and tumor control probability (TCP with SF=0.28) were computed. 
Tumors were stratified according to peripheral ('island', N=39), lung-
wall (attached to the rib-cage, N=44) and central locations (N=50), as 
well as tumor size and mean plan field size.  
Results: GEUD values for the EPL-1D algorithm were based on 
prescription doses and ranged from 48-49 Gy for all cases. MC-
computed gEUD decreased significantly with decreasing tumor size; 
values in Gy were 41.9+3.6 for average plan field widths (FW) 
between 3-5 cm; 43.8+3.2 (5>FW>7 cm); 45.9+3.3 between (7>FW>10 
cm). TCP’s for the EPL-1D algorithm increased with decreasing tumor 
size with values of 0.88+0.04 (3>FW>5 cm); 0.85+0.03 (5>FW>7 cm); 
0.80+0.05 (7>FW>10 cm). On the other hand, MC-computed TCP’s 
remained relatively constant as a function of tumor size; values were 
0.77+0.07 (3>FW>5 cm); 0.76+0.05 (5>FW>7 cm); 0.76+0.05 (7>FW>10 
cm). Results were consistent for 'island', lung wall and central tumors. 
There was no correlation between tumor size and local control rate 
among the 92% of patients who were controlled locally at 2-years, 
which is consistent with the MC-calculated TCPs. Note, however, that 
MC-computed gEUDs were significantly lower for smaller tumor sizes. 
This suggests that although smaller tumors were receiving much lower 
doses (on average, 10.5 Gy vs. 12 Gy per fxn), they were being 
controlled. These findings are consistent with radiobiology; smaller 
tumors have fewer tumor cells and therefore require lower doses to 
be controlled relative to larger tumors. Results are also suggestive 
that dose could be tailored according to size and location of the 
tumor, i.e. one size does not need to fit all. We speculate as well that 
the concept of minimally ablative dose (MAD) is perhaps not an 
unreasonable approach to consider for smaller tumors. Dose de-
escalation for smaller tumors, based on the mimimum ablative dose is 
likely to be clinically relevant for tumors situated close to normal 
organs (e.g. ribs, centrally located airways) and for patients being 
treated for recurrent disease.  
  
PTV 
Volume  
(cm3) 
Avg. 
Field  
(cm) 
EPL-
1D_gEUD 
(Gy) 
EPL-1D_TCP 
(SF=0.28) 
MC_gEUD 
(Gy) 
MC_TCP 
(SF=0.28) 
Lung-
island N=39
27.6 ± 
29.5 
5.0 ±
1.0 48.7 ± 2.4 0.87 ± 0.04 41.3 ± 3.3 0.74 ± 0.06 
Lung-
wall N=44
53.4 ± 
59.8 
5.9 ±
1.5 49.1 ± 1.7 0.85 ± 0.04 44.7 ± 3.2 0.78 ± 0.05 
Lung-
central N=50
45.6 ± 
41.6 
5.8 ±
1.4 48.6 ± 2.5 0.84 ± 0.05 43.9 ± 3.5 0.77 ± 0.06 
  
Conclusions: Retrospective dose analysis of 133 NSCLC patients 
treated with SBRT is suggestive that individualization of doses based 
on tumor size and location may be a feasible approach toward 
achieving equivalent local control and possibly reducing toxicity based 
on the clinical circumstances.  
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Purpose/Objective: Current toxicity models in prostate cancer 
radiotherapy, based on dose-volume histograms, do not enable to 
identify region in the rectum involved in bleeding. Localize such 
regions may be crucial in IMRT to decrease rectal toxicity. The goals 
of this study were: 
- firstly to assess the rectal bleeding/local dose correlation using 
voxel wise statistics on several anatomically different templates (thus 
avoiding a specific template effect), 
- secondly to back propagate the significant regions found on these 
templates to a specific patient (pts). 
Materials and Methods: A total of 93 patients receiving a total dose of 
80Gy in the prostate by IMRT were included in the analysis. Rectal 
bleeding (RB) at two years was analyzed (> grade 1). The series was 
divided in 2 cohorts: one for training (63 pts) and the other one for 
testing (30 pts).  A total of 63 randomly chosen individuals (12/51 
with/without RB) 3D CT scans and planned dose were non-rigidly 
registered towards 10 templates in a 3 step process: one rigid 
registration and two elastic registrations (demons algorithm). The 
registrations were designed to ensure accurate alignments of rectums 
and dose distributions. Dice scores and Dose-Organs Overlap (DOO) 
were computed on the rectum for each pt on the 10 templates to 
assess the accuracy of the registration. 
Two-sampled t-tests were then performed on each template at a 
voxel-basis leading to the computation of 3D maps for both, the dose 
differences (and the p-values) between the mean dose of pts having 
or not toxicity. Significant regions (p<0.01) were then characterized in 
terms of absolute volume, mean dose difference and localization in 
the rectum. The last one was defined as the distance of the significant 
region to the prostate and the seminal vesicles surfaces. 
The 10 significant regions from each template were then back 
propagated, using the same registration method, on 30 'test patients' 
(6/24 with/without RB) leading to the computation of a probability 
map of the significant region on the rectum for each test patient. The 
significant regions for toxicity were then delineated using a majority 
vote approach. 
Results:  
Median follow-up was 31 months (6 to 64). Two year RB rate were 
20%(95% CI: 12-27). 
1. Median Dice and DOO were 0.98 (sd 0.01) and 0.97 (sd 0.02).  
2. Significant differences of dose related with toxicity were found 
in large regions on the 10 templates, corresponding to 5.95% of 
the rectal volume (in average). The anterior wall of the rectum 
appears involved in RB on the 10 templates (fig): 92.17% (sd 6.3) 
of the volume of the significant region were localized within the 
first 15mm of the rectum close to the prostate. In these regions, 
pts with RB received 6.7Gy (sd 1.3) more than pts without RB. 
Conclusions: The anterior wall of the rectum appears strongly 
involved in RB. Our templates constitute a library of RB correlated 
region, which can be used to more precisely identify the region at risk 
of rectal bleeding for a given patient. This new approach opens the 
way for patient specific treatment by enabling to add IMRT constraints 
on region likely responsible of RB. 
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Purpose/Objective: Many dose-limiting normal tissues in radiotherapy 
display considerable internal organ motion during a course of 
treatment, potentially deteriorating the relations between dose-
volume parameters and morbidity. To address this issue, we have 
previously developed a motion simulation model and validated and 
applied it on the rectum geometries in the planning CT scans in a 
cohort of prostate cancer patients. In this present study we apply this 
model to compare the associations with morbidity of the planned vs. 
motion-inclusive dose distributions in two cohorts of patients 
prospectively followed with respect to a broader spectrum of rectal 
morbidity endpoints. 
Materials and Methods: The patients in the two included cohorts 
(Cohort I: 192 patients; Cohort II:87 patients) were previously treated 
with RT for localised prostate cancer to prescribed doses of 70 vs. 74 
Gy. The dose-response relations for the planned as well as simulated 
motion-inclusive rectal dose-volume histograms (DVHs) were 
associated with six rectal morbidity endpoints (Cohort I: RTOG gastro-
intestinal (GI) toxicity, stool frequency,mucosal loss, tenesmus, 
sphincter control and late rectal bleeding (LRB); Cohort II: LRB). The 
motion-inclusive dose distributions were obtained from simulations of 
small, moderate and large motion magnitudes applied to the planned 
dose distributions, using the previously developed and validated 
model.Additionally the data was evaluated with a probit NTCP model 
using the QUANTEC recommended rectal parameters (TD50=76.9, 
m=0.13, n=0.09).  
Results: Statistically significant associations with the studied 
endpoints were obtained at high doses (> 55Gy) using both the 
planned and the simulated motion-inclusive dose distributions, with 
the strongest associations observed for RTOG GI toxicity and stool 
frequency (Spearman's rank correlation coefficient, Rs=0.13-0.21 and 
Rs=0.14-0.16). Within the high dose region the associations with 
morbidity using the planned or the motion-inclusive DVHs with either 
small or moderate motion magnitudes were stronger than the 
associations seen when simulating large motion. Using the probit NTCP 
model the strongest associations were observed for tenesmus 
(Rs=0.14, p=0.03) and LRB (Rs=0.12, p=0.13). 
Conclusions: Equally strong associations with rectal morbidity were 
observed for high doses (>55 Gy), for the planned dose distributions 
and the simulated dose distributions including small and moderate 
rectal motion. Using a probit model with the QUANTEC recommended 
parameters the strongest significant associations were obtained for 
tenesmus. 
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Purpose/Objective: The Linear-Quadratic (LQ)-based ‘Withers’ iso-
effect formula (WIF) is the standard method for deriving a new 
(tumour) dose prescription such that there is normal-tissue (NT) iso-
effect when changing the fraction size and/or number. However, the 
WIF is invalid unless the NT receives a uniform dose equal to the 
tumour dose, or, the NT response is solely determined by the 
maximum NT dose (100% serial). For parallel/quasi-parallel NTs the 
WIF yields highly conservative hypofractionation prescriptions. Our 
aim was to find a method to calculate NT iso-effective fractionation 
schemes which correctly account for arbitrary NT dose distributions 
and ‘architecture’. 
Materials and Methods: We propose a generalized WIF (gWIF) which 
retains the tumour prescription doses but replaces the intrinsic 
fractionation sensitivity measure (α/β) by a new concept: the normal-
tissue effective fractionation sensitivity, (α/β)NTeff, which takes into 
account both the dose heterogeneity in, and the volume effect of, the 
late-responding normal tissue in question. Assuming a power-law dose-
volume response model, we have derived a closed-form analytical 
expression for (α/β)NTeff which ensures exact NT iso-effect, for an 
arbitrary dose distribution and arbitrary volume-effect parameter n. 
Results: As n is varied, (α/β)NTeff increases from its intrinsic value at n 
= 0 (100% serial NT) to values close to or even exceeding the tumour 
(α/β)T at n = 1 (100% parallel NT), with the highest (α/β)NTeff 
corresponding to highly conformal dose distributions. Assuming an 
intrinsic (α/β)NT = 3 Gy, for two IMRT plans for non-small-cell lung 
tumours, with radiation pneumonitis as endpoint (n = 1), in the 
moderately conformal case (α/β)NTeff = 4.5 Gy, whereas for the highly 
conformal plan we obtained (α/β)NTeff = 8.5 Gy. For three typical SABR 
plans, we obtained values of (α/β)NTeff 7.0 to 8.9 Gy depending on the 
DVHs for the non-involved (paired) lungs. Note that our (α/β)NTeff is 
independent of the choice of fractionation scheme. 
Conclusions: The (α/β)NTeff concept embodies an explicit relationship 
between the degree of NT dose heterogeneity, the volume effect 
associated with the clinical endpoint in question, and the 
fractionation sensitivity. The conventional WIF can be retained for 
exact NT iso-effect calculations simply by replacing the intrinsic 
(α/β)NT by (α/β)NTeff. Situations where hypofractionation can (or 
cannot) be safely applied can now be easily identified. Furthermore, 
should the LQ expression over-predict cell killing at large fraction 
sizes, the predictions of the generalized WIF become even ‘safer’.  
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Purpose/Objective: To compare gross tumor volume (GTV) of 
laryngeal and hypopharyngeal carcinoma delineated on MRI with the 
tumor volume of pathology from laryngectomy specimen. 
Materials and Methods: From 22 patients (mean age, 62.3; range, 52 -
79 years; 20 males and 2 females) with T3 (n=5) or T4 (n=17) 
squamous cell carcinoma of the larynx (5 transglottic-, 6 supraglottic-, 
1 glottic carcinoma) or hypopharynx (n=10), the specimen was 
obtained after total laryngectomy. The sliced specimen was processed 
and 3-D reconstructed according to our pathology validation protocol 
and registered to in vivo MR-images with an accuracy of 3 mm in the 
cartilage skeleton. Hematoxylin-eosin (H&E) stained sections were 
obtained and tumor volume on these sections was delineated by a 
pathologist.  
Prior to laryngectomy, a high-resolution 1.5 Tesla MRI-scan was 
performed in a head-and-shoulder mask with a two-element surface 
receiver coil. T2w images and T1w images before and after injection 
of gadolinium were obtained. The mean time interval between the 
MRI-scan and operation was 10.8 days, range 2-34 days. 
Three experienced head-and-neck specialists (2 radiation oncologists, 
1 radiologist) delineated the GTV on MRI after consensus about 
guidelines according to delineation of the GTV in clinical practice. 
Results: The mean tumor volume (27.1 ml, SD 18.2) delineated by the 
observers were almost doubled compared to tumor volumes 
delineated by the pathologist (15.5 ml, SD 15.3). For all patients, the 
GTV of the observers exceeded the tumor volume of the pathologist 
(figure 1). The GTV’s delineated on MRI included tumor tissue as well 
as non-tumorous tissues e.g.; edema and necrosis, enlarging the GTV 
compared to pathology. To increase accuracy in tumor delineation, a 
study is currently performed in our institute to develop MRI-based 
guidelines for interpretation and delineation of head and neck cancer. 
 
  
Figure 1. The GTV of a T3 hypopharyngeal carcinoma delineated on 
transversal MR-image (1a: T1-weighted+gadolinium, 1b: T1-
weigthedand 1c: T2-weighted) by three observers. MR-images are 
registered to the transversal gross-pathology photos (2a) and 
transversal H&E-stained sections(2b) of the same tumor on which true 
tumor is indicated. 
Conclusions: Gross tumor volume on MRI is overestimated in clinical 
radiotherapy practice compared to tumor volume of the pathology.  
